Table 5.
Source of variation | Total variation (%) | P-value | P-value summary | Significant? |
---|---|---|---|---|
GNP-lestaurtinib, days 1–14 | ||||
OCI-AML3 | ||||
Interaction | 39.61 | <0.0001 | **** | Yes |
Row factor | 33.10 | <0.0001 | **** | Yes |
Column factor | 26.77 | <0.0001 | **** | Yes |
GNP-sorafenib, days 1–14 | ||||
OCI-AML3 | ||||
Interaction | 39.06 | <0.0001 | **** | Yes |
Row factor | 29.22 | <0.0001 | **** | Yes |
Column factor | 25.70 | <0.0001 | **** | Yes |
GNP-quizartinib, days 1–14 | ||||
OCI-AML3 | ||||
Interaction | 38.53 | <0.0001 | **** | Yes |
Row factor | 29.31 | <0.0001 | **** | Yes |
Column factor | 25.25 | <0.0001 | **** | Yes |
GNP-lestaurtinib, days 1–14 | ||||
THP1 | ||||
Interaction | 38.72 | <0.0001 | **** | Yes |
Row factor | 29.99 | <0.0001 | **** | Yes |
Column factor | 25.55 | <0.0001 | **** | Yes |
GNP-sorafenib, days 1–14 | ||||
THP1 | ||||
Interaction | 38.61 | <0.0001 | **** | Yes |
Row factor | 30.84 | <0.0001 | **** | Yes |
Column factor | 25.37 | <0.0001 | **** | Yes |
GNP-quizartinib, days 1–14 | ||||
THP1 | ||||
Interaction | 37.63 | <0.0001 | **** | Yes |
Row factor | 31.59 | <0.0001 | **** | Yes |
Column factor | 25.44 | <0.0001 | **** | Yes |
Note:
Statistically significant.
Abbreviations: GNP, gold nanoparticle; TKI, tyrosine kinase inhibitor.